曲美他嗪辅助治疗对急性脑梗死患者临床疗效、内皮细胞功能和炎症因子水平的影响  

Effects of Trimetazidine Adjuvant Therapy on Clinical Efficacy,Endothelial Cell Function and Inflammatory Factor Level in Patients with Acute Cerebral Infarction

作　　者：牛晓露[1] 刘丽[1] 李合华[1] NIU Xiao-lu;LIU Li;LI He-hua(Department of Neurology,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China)

机构地区：[1]新乡医学院第一附属医院神经内科,新乡453100

出　　处：《中国合理用药探索》2021年第12期68-72,共5页Chinese Journal of Rational Drug Use

摘　　要：目的:探讨曲美他嗪辅助治疗对急性脑梗死(ACI)患者的临床疗效、内皮细胞功能和炎症因子水平的影响。方法:选择2018年10月~2019年6月就诊于本院神经内科的108例ACI患者作为研究对象,采用随机数字表法将其分为对照组和观察组,各54例。对照组采用常规治疗,观察组在对照组基础上予以盐酸曲美他嗪片口服。比较两组临床疗效;观察两组治疗前和治疗后内皮细胞功能[血管性假血友病因子(vWF)、可溶性血栓调节蛋白(sTM)]和炎症因子[白细胞介素-6(IL-6)、白细胞介素-17(IL-17)、肿瘤坏死因子-α(TNF-α)]水平的变化;记录两组治疗期间不良反应发生情况。结果:观察组总有效率(83.33%)高于对照组(64.82%,P<0.05)。治疗后,两组vWF、sTM、IL-6、IL-17、TNF-α水平低于治疗前,且观察组低于对照组(P<0.05)。治疗期间,两组不良反应总发生率比较无统计学差异(P>0.05)。结论:曲美他嗪辅助治疗ACI可提高临床疗效,有效改善内皮细胞功能并减轻机体炎症状态,且安全性较高。Objective:To explore the effects of trimetazidine adjuvant therapy on clinical efficacy,endothelial cell function and inflammatory factor level in patients with acute cerebral infarction(ACI).Methods:A total of 108 patients with ACI from October,2018 to June,2019 in the department of neurology of our hospital were selected as the research subjects.And they were divided into control group and observation group according to random number table method,with 54 cases in each group.The control group was treated with routine treatments,and the observation group was treated with trimetazidine dihydrochloride tablets(oral administration)on the basis of the control group.The clinical efficacy of the two groups was compared.The changes of endothelial cell function[von Willebrand factor(vWF),soluable Thrombomodulin(sTM)]and inflammatory factor[interleukin-6(IL-6),interleukin-17(IL-17),tumor necrosis factor-α(TNF-α)]levels between the two groups were observed before and after treatment.The adverse reactions of the two groups during treatment were recorded.Results:The total effective rate of the observation group(83.33%)was higher than the control group(64.82%,P<0.05).After treatment,the levels of vWF,sTM,IL-6,IL-17 and TNF-αin the two groups were lower than those before treatment,and the observation group was lower than the control group(P<0.05).During treatment,there was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Trimetazidine adjuvant treatment of ACI can improve clinical efficacy,effectively improve endothelial cell function and reduce the inflammatory state of the body,with high safety.

关 键 词：急性脑梗死 曲美他嗪 临床疗效 内皮细胞功能 炎症因子 不良反应 

分 类 号：R972[医药卫生—药品]